vTv Therapeutics Inc. (VTVT)
| Market Cap | 415.72M +183.9% |
| Revenue (ttm) | 36.84M +216,600.0% |
| Net Income | 2.25M |
| EPS | 0.21 |
| Shares Out | 12.41M |
| PE Ratio | 155.97 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 28,804 |
| Open | 33.70 |
| Previous Close | 33.72 |
| Day's Range | 32.94 - 34.09 |
| 52-Week Range | 14.00 - 44.00 |
| Beta | 0.26 |
| Analysts | Strong Buy |
| Price Target | 53.00 (+58.21%) |
| Earnings Date | May 13, 2026 |
About VTVT
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to dev... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for VTVT stock is "Strong Buy." The 12-month stock price target is $53.0, which is an increase of 58.21% from the latest price.
News
vTv Therapeutics reports Q1 EPS $1.65, consensus 21c
Reports Q1 revenue $36.84M, consensus $10M. “We are executing with focus and discipline as we advance cadisegliatin, a potentially transformative, first-in-class oral therapy for people living with ty...
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13, ...
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in...
vTv Therapeutics to Participate in Upcoming May Investor Conferences
HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in...
vTv Therapeutics to Participate in the 38th Annual ROTH Conference
HIGH POINT, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-...
vTv Therapeutics initiated with an Outperform at Evercore ISI
Evercore ISI initiated coverage of vTv Therapeutics (VTVT) with an Outperform rating and $44 price target Cadisegliatin, a potential first-in-class, once-daily, oral, liver-selective glucokinase activ...
vTv Therapeutics price target raised to $55 from $35 at Alliance Global
Alliance Global raised the firm’s price target on vTv Therapeutics (VTVT) to $55 from $35 and keeps a Buy rating on the shares. The company’s Q4 report highlighted the ongoing…
vTv Therapeutics reports Q4 EPS (58c), consensus ($1.09)
The company’s cash position as of December 31, 2025, was $88.9M compared to $36.7M as of December 31, 2024. “In 2025, vTv delivered meaningful clinical and corporate progress that positions…
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Received $20.0 million in February 2026 from Newsoara under an amended licensing agreement Expect to complete enrollment in the CATT1 Phase 3 trial in the third quarter of 2026 Strengthened balance s...
vTv Therapeutics to Participate in Upcoming Investor Conferences
HIGH POINT, N.C., Feb. 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-i...
vTv Therapeutics expanded its license agreement with Newsoara Biopharma
vTv Therapeutics (VTVT) announced that it has expanded its license agreement with Newsoara Biopharma to provide Newsoara with global rights to the Company’s PDE4 inhibitor, HPP737. Pursuant to the ame...
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million u...
vTv Therapeutics price target raised to $49 from $40 at BTIG
BTIG analyst Kambiz Yazdi raised the firm’s price target on vTv Therapeutics (VTVT) to $49 from $40 and keeps a Buy rating on the shares. The recent comments from the…
vTv Therapeutics initiated with a Buy at Roth Capital
Roth Capital initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $58 price target The firm believes cadisegliatin is positioned to become the first approved oral adjunct for…
vTv Therapeutics initiated with a Buy at TD Cowen
TD Cowen initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $67 price target The firm thinks the company’s oral hepatoselective glucokinase activator, cadisegliatin will reduce level ...
vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on vTv Therapeutics (VTVT) to $47 from $36 and keeps a Buy rating on the shares to reflect higher conviction in the long-term…
vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi
vTv Therapeutics (VTVT) announced a Phase 2 clinical study protocol developed in collaboration with M42’s Insights Research Organization & Solutions, a United Arab Emirates-based contract research org...
vTv Therapeutics and M42's IROS Announce Submission of Phase 2 Clinical Study Protocol for Cadisegliatin in Type 2 Diabetes to the United Arab Emirates Department of Health
Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D Trial to assess cadisegliatin as potential adjunctive therapy to insulin in patients with T2D
vTv Therapeutics initiated with a Buy at BTIG
BTIG initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $40 price target vTv is a clinical-stage biotech company developing oral drugs for metabolic and inflammatory diseases, the…
vTv Therapeutics reports Q3 EPS ($1.08), consensus (98c)
“The third quarter saw a series of meaningful achievements,” said Paul Sekhri, Chairman, President and CEO of vTv Therapeutics (VTVT). “During the quarter, we randomized our first patient in the…
vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 $80 million private placement strengthens balance sheet and supports Phase 3 CATT1 completion Announced issua...
vTv Therapeutics trading resumes
09:35 EST vTv Therapeutics (VTVT) trading resumes
vTv Therapeutics trading halted, volatility trading pause
09:30 EST vTv Therapeutics (VTVT) trading halted, volatility trading pause
vTv Therapeutics announces three appointments to Scientific Advisory Board
vTv Therapeutics (VTVT) announced the appointment of Alfonso Galderisi, MD, PhD, Mark Evans, MD, Chantal Mathieu, MD, PhD, and Klara Klein, MD, PhD, to its Scientific Advisory Board. The SAB,…
vTv Therapeutics Announces New Appointments to its Scientific Advisory Board
Board to offer guidance on clinical development of cadisegliatin for type 1 diabetes as company has initiated Phase 3 trials Board to offer guidance on clinical development of cadisegliatin for type 1...